The Chk2 protein kinase

DNA Repair

Volumn 3, Issue 8-9, 2004, Pages 1039-1047

  Ahn, Jinwoo ^a   Urist, Marshall ^a   Prives, Carol ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Apoptosis; Checkpoint kinase 2; Phosphorylation

Indexed keywords

ATM PROTEIN; BRCA1 PROTEIN; CAMPTOTHECIN; CHECKPOINT KINASE 2; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; ETOPOSIDE; HYDROXYUREA; KARYOPHERIN ALPHA; KI 67 ANTIGEN; KINESIN; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; PROTEIN MLH1; PROTEIN MSH2; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2F1;

AMINO TERMINAL SEQUENCE; APOPTOSIS; BETA SHEET; CANCER INHIBITION; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; CARBOXY TERMINAL SEQUENCE; CATALYSIS; DNA DAMAGE; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME RELEASE; ENZYME SUBSTRATE; FAMILIAL CANCER; GENE INACTIVATION; HUMAN; MISSENSE MUTATION; MITOSIS INHIBITION; NIJMEGEN BREAKAGE SYNDROME; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; APOPTOSIS; BINDING SITES; CATALYTIC DOMAIN; CELL CYCLE; DNA DAMAGE; DNA REPAIR; ENZYME ACTIVATION; HUMANS; MICE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; MUTATION; NEOPLASMS; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 3242884449     PISSN: 15687864     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dnarep.2004.03.033     Document Type: Review

References (114)

1. Zhou B.B., Elledge S.J. The DNA damage response: putting checkpoints in perspective. Nature. 408:2000;433-439
2. Bradbury J.M., Jackson S.P. The complex matter of DNA double-strand break detection. Biochem Soc Trans. 31:2003;40-44
3. Thompson L.H., Schild D. Recombinational DNA repair and human disease. Mutat Res. 509:2002;49-78
4. Zhou B.B., Anderson H.J., Roberge M. Targeting DNA checkpoint kinases in cancer therapy. Cancer Biol Ther. 2:2003;S16-S22
5. Matsuoka S., Huang M., Elledge S.J. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science. 282:1998;1893-1897
6. Kim S.T., Lim D.S., Canman C.E., Kastan M.B. Substrate specificities and identification of putative substrates of ATM kinase family members. J Biol Chem. 274:1999;37538-37543
7. O'Neill T., Dwyer A.J., Ziv Y., Chan D.W., Lees-Miller S.P., Abraham R.H., Lai J.H., Hill D., Shiloh Y., Cantley L.C., Rathbun G.A. Utilization of oriented peptide libraries to identify substrate motifs selected by ATM. J Biol Chem. 275:2000;22719-22727
8. Li J., Lee G.I., Van Doren S.R., Walker J.C. The FHA domain mediates phosphoprotein interactions. J Cell Sci. 113(Pt 23):2000;4143-4149
9. Durocher D., Henckel J., Fersht A.R., Jackson S.P. The FHA domain is a modular phosphopeptide recognition motif. Mol Cell. 4:1999;387-394
10. Durocher D., Taylor I.A., Sarbassova D., Haire L.F., Westcott S.L., Jackson S.P., Smerdon S.J., Yaffe M.B. The molecular basis of FHA domain:phosphopeptide binding specificity and implications for phospho-dependent signaling mechanisms. Mol Cell. 6:2000;1169-1182
11. Li J., Williams B.L., Haire L.F., Goldberg M., Wilker E., Durocher D., Yaffe M.B., Jackson S.P., Smerdon S.J. Structural and functional versatility of the FHA domain in DNA-damage signaling by the tumor suppressor kinase Chk2. Mol Cell. 9:2002;1045-1054
12. Stavridi E.S., Huyen Y., Loreto I.R., Scolnick D.M., Halazonetis T.D., Pavletich N.P., Jeffrey P.D. Crystal structure of the FHA domain of the Chfr mitotic checkpoint protein and its complex with tungstate. Structure (Camb). 10:2002;891-899
13. Liao H., Byeon I.J., Tsai M.D. Structure and function of a new phosphopeptide-binding domain containing the FHA2 of Rad53. J Mol Biol. 294:1999;1041-1049
14. Liao H., Yuan C., Su M.I., Yongkiettrakul S., Qin D., Li H., Byeon I.J., Pei D., Tsai M.D. Structure of the FHA1 domain of yeast Rad53 and identification of binding sites for both FHA1 and its target protein Rad9. J Mol Biol. 304:2000;941-951
15. Wang P., Byeon I.J., Liao H., Beebe K.D., Yongkiettrakul S., Pei D., Tsai M.D. II Structure and specificity of the interaction between the FHA2 domain of Rad53 and phosphotyrosyl peptides. J Mol Biol. 302:2000;927-940
16. Byeon I.J., Yongkiettrakul S., Tsai M.D. Solution structure of the yeast Rad53 FHA2 complexed with a phosphothreonine peptide pTXXL: comparison with the structures of FHA2-pYXL and FHA1-pTXXD complexes. J Mol Biol. 314:2001;577-588
17. Yuan C., Yongkiettrakul S., Byeon I.J., Zhou S., Tsai M.D. Solution structures of two FHA1-phosphothreonine peptide complexes provide insight into the structural basis of the ligand specificity of FHA1 from yeast Rad53. J Mol Biol. 314:2001;563-575
18. Durocher D., Jackson S.P. The FHA domain. FEBS Lett. 513:2002;58-66
19. Bartek J., Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell. 3:2003;421-429
20. Evans S.C., Lozano G. The Li-Fraumeni syndrome: an inherited susceptibility to cancer. Mol Med Today. 3:1997;390-395
21. Bell D.W., Varley J.M., Szydlo T.E., Kang D.H., Wahrer D.C., Shannon K.E., Lubratovich M., Verselis S.J., Isselbacher K.J., Fraumeni J.F., Birch J.M., Li F.P., Garber J.E., Haber D.A. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science. 286:1999;2528-2531
22. Vahteristo P., Bartkova J., Eerola H., Syrjakoski K., Ojala S., Kilpivaara O., Tamminen A., Kononen J., Aittomaki K., Heikkila P., Holli K., Blomqvist C., Bartek J., Kallioniemi O.P., Nevanlinna H. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet. 71:2002;432-438
23. Meijers-Heijboer H., Wijnen J., Vasen H., Wasielewski M., Wagner A., Hollestelle A., Elstrodt F., van den Bos R., de Snoo A., Fat G.T., Brekelmans C., Jagmohan S., Franken P., Verkuijlen P., van den Ouweland A., Chapman P., Tops C., Moslein G., Burn J., Lynch H., Klijn J., Fodde R., Schutte M. The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. Am J Hum Genet. 72:2003;1308-1314
24. Meijers-Heijboer H., van den Ouweland A., Klijn J., Wasielewski M., de Snoo A., Oldenburg R., Hollestelle A., Houben M., Crepin E., van Veghel-Plandsoen M., Elstrodt F., van Duijn C., Bartels C., Meijers C., Schutte M., McGuffog L., Thompson D., Easton D., Sodha N., Seal S., Barfoot R., Mangion J., Chang-Claude J., Eccles D., Eeles R., Evans D.G., Houlston R., Murday V., Narod S., Peretz T., Peto J., Phelan C., Zhang H.X., Szabo C., Devilee P., Goldgar D., Futreal P.A., Nathanson K.L., Weber B., Rahman N., Stratton M.R. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet. 31:2002;55-59
25. Sodha N., Bullock S., Taylor R., Mitchell G., Guertl-Lackner B., Williams R.D., Bevan S., Bishop K., McGuire S., Houlston R.S., Eeles R.A. CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumours. Br J Cancer. 87:2002;1445-1448
26. Schutte M., Seal S., Barfoot R., Meijers-Heijboer H., Wasielewski M., Evans D.G., Eccles D., Meijers C., Lohman F., Klijn J., van den Ouweland A., Futreal P.A., Nathanson K.L., Weber B.L., Easton D.F., Stratton M.R., Rahman N. Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility. Am J Hum Genet. 72:2003;1023-1028
27. Dong X., Wang L., Taniguchi K., Wang X., Cunningham J.M., McDonnell S.K., Qian C., Marks A.F., Slager S.L., Peterson B.J., Smith D.I., Cheville J.C., Blute M.L., Jacobsen S.J., Schaid D.J., Tindall D.J., Thibodeau S.N., Liu W. Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet. 72:2003;270-280
28. Wu X., Webster S.R., Chen Characterization of tumor-associated Chk2 mutations J. J Biol Chem. 276:2001;2971-2974
29. Lee S.B., Kim S.H., Bell D.W., Wahrer D.C., Schiripo T.A., Jorczak M.M., Sgroi D.C., Garber J.E., Li F.P., Nichols K.E., Varley J.M., Godwin A.K., Shannon K.M., Harlow E., Haber D.A. Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome. Cancer Res. 61:2001;8062-8067
30. Matsuoka S., Nakagawa T., Masuda A., Haruki N., Elledge S.J., Takahashi T. Reduced expression and impaired kinase activity of a Chk2 mutant identified in human lung cancer. Cancer Res. 61:2001;5362-5365
31. Falck J., Lukas C., Protopopova M., Lukas J., Selivanova G., Bartek J. Functional impact of concomitant versus alternative defects in the Chk2- p53 tumour suppressor pathway. Oncogene. 20:2001;5503-5510
32. Falck J., Mailand N., Syljuasen R.G., Bartek J., Lukas J. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature. 410:2001;842-847
33. d'Adda di Fagagna F., Reaper P.M., Clay-Farrace L., Fiegler H., Carr P., Von Zglinicki T., Saretzki G., Carter N.P., Jackson S.P. A DNA damage checkpoint response in telomere-initiated senescence. Nature. 426:2003;194-198
34. Oh H., Wang S.C., Prahash A., Sano M., Moravec C.S., Taffet G.E., Michael L.H., Youker K.A., Entman M.L., Schneider M.D. Telomere attrition and Chk2 activation in human heart failure. Proc Natl Acad Sci USA. 100:2003;5378-5383
35. Banin S., Moyal L., Shieh S., Taya Y., Anderson C.W., Chessa L., Smorodinsky N.I., Prives C., Reiss Y., Shiloh Y., Ziv Y. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science. 281:1998;1674-1677
36. Canman C.E., Lim D.S., Cimprich K.A., Taya Y., Tamai K., Sakaguchi K., Appella E., Kastan M.B., Siliciano J.D. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science. 281:1998;1677-1679
37. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer. 3:2003;155-168
38. Brown A.L., Lee C.H., Schwarz J.K., Mitiku N., Piwnica-Worms H., Chung J.H. A human Cds1-related kinase that functions downstream of ATM protein in the cellular response to DNA damage. Proc Natl Acad Sci USA. 96:1999;3745-3750
39. Chaturvedi P., Eng W.K., Zhu Y., Mattern M.R., Mishra R., Hurle M.R., Zhang X., Annan R.S., Lu Q., Faucette L.F., Scott G.F., Li X., Carr S.A., Johnson R.K., Winkler J.D., Zhou B.B. Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene. 18:1999;4047-4054
40. Ahn J.Y., Schwarz J.K., Piwnica-Worms H., Canman C.E. Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res. 60:2000;5934-5936
41. Matsuoka S., Rotman G., Ogawa A., Shiloh Y., Tamai K., Elledge S.J. Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci USA. 97:2000;10389-10394
42. Melchionna R., Chen X.B., Blasina A., McGowan C.H. Threonine 68 is required for radiation-induced phosphorylation and activation of Cds1. Nat Cell Biol. 2:2000;762-765
43. Ahn J.Y., Li X., Davis H.L., Canman C.E. Phosphorylation of threonine 68 promotes oligomerization and autophosphorylation of the Chk2 protein kinase via the forkhead- associated domain. J Biol Chem. 277:2002;19389-19395
44. Xu X., Tsvetkov L.M., Stern D.F. Chk2 activation and phosphorylation- dependent oligomerization. Mol Cell Biol. 22:2002;4419-4432
45. Ahn J., Prives C. Checkpoint kinase 2 (Chk2) monomers or dimers phosphorylate Cdc25C after DNA damage regardless of threonine 68 phosphorylation. J Biol Chem. 277:2002;48418-48426
46. Lee C.H., Chung J.H. The hCds1 (Chk2)-FHA domain is essential for a chain of phosphorylation events on hCds1 that is induced by ionizing radiation. J Biol Chem. 276:2001;30537-30541
47. Schwarz J.K., Lovly C.M., Piwnica-Worms H. Regulation of the Chk2 Protein Kinase by Oligomerization-Mediated cis- and trans-Phosphorylation. Mol Cancer Res. 1:2003;598-609
48. Wu X., Chen J. Autophosphorylation of checkpoint kinase 2 at serine 516 is required for radiation-induced apoptosis. J Biol Chem. 278:2003;36163-36168
49. Lou Z., Minter-Dykhouse K., Wu X., Chen J. MDC1 is coupled to activated CHK2 in mammalian DNA damage response pathways. Nature. 421:2003;957-961
50. Tsvetkov L., Xu X., Li J., Stern D.F. Polo-like kinase 1 and Chk2 interact and co-localize to centrosomes and the midbody. J Biol Chem. 278:2003;8468-8475
51. Xie S., Wu H., Wang Q., Kunicki J., Thomas R.O., Hollingsworth R.E., Cogswell J., Dai W. Genotoxic stress-induced activation of Plk3 is partly mediated by Chk2. Cell Cycle. 1:2002;424-429
52. Bahassi el M., Conn C.W., Myer D.L., Hennigan R.F., McGowan C.H., Sanchez Y., Stambrook P.J. Mammalian Polo-like kinase 3 (Plk3) is a multifunctional protein involved in stress response pathways. Oncogene. 21:2002;6633-6640
53. Zannini L., Lecis D., Lisanti S., Benetti R., Buscemi G., Schneider C., Delia D. Karyopherin-alpha2 protein interacts with Chk2 and contributes to its nuclear import. J Biol Chem. 278:2003;42346-42351
54. O'Neill T., Giarratani L., Chen P., Iyer L., Lee C.H., Bobiak M., Kanai F., Zhou B.B., Chung J.H., Rathbun G.A. Determination of Substrate Motifs for Human Chk1 and hCds1/Chk2 by the Oriented Peptide Library Approach. J Biol Chem. 277:2002;16102-16115
55. Seo G.J., Kim S.E., Lee Y.M., Lee J.W., Lee J.R., Hahn M.J., Kim S.T. Determination of substrate specificity and putative substrates of Chk2 kinase. Biochem Biophys Res Commun. 304:2003;339-343
56. Blasina A., de Weyer I.V., Laus M.C., Luyten W.H., Parker A.E., McGowan C.H. A human homologue of the checkpoint kinase Cds1 directly inhibits Cdc25 phosphatase. Curr Biol. 9:1999;1-10
57. Sorensen C.S., Syljuasen R.G., Falck J., Schroeder T., Ronnstrand L., Khanna K.K., Zhou B.B., Bartek J., Lukas J. Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. Cancer Cell. 3:2003;247-258
58. Busino L., Donzelli M., Chiesa M., Guardavaccaro D., Ganoth D., Dorrello N.V., Hershko A., Pagano M., Draetta G.F. Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage. Nature. 426:2003;87-91
59. Jin J., Shirogane T., Xu L., Nalepa G., Qin J., Elledge S.J., Harper J.W. SCFbeta-TRCP links Chk1 signaling to degradation of the Cdc25A protein phosphatase. Genes Dev. 17:2003;3062-3074
60. Zhou B.B., Chaturvedi P., Spring K., Scott S.P., Johanson R.A., Mishra R., Mattern M.R., Winkler J.D., Khanna K.K. Caffeine abolishes the mammalian G(2)/M DNA damage checkpoint by inhibiting ataxia-telangiectasia-mutated kinase activity. J Biol Chem. 275:2000;10342-10348
61. Peng C.Y., Graves P.R., Thoma R.S., Wu Z., Shaw A.S., Piwnica-Worms H. Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science. 277:1997;1501-1505
62. Dalal S.N., Schweitzer C.M., Gan J., DeCaprio J.A. Cytoplasmic localization of human cdc25C during interphase requires an intact 14-3-3 binding site. Mol Cell Biol. 19:1999;4465-4479
63. Stevens C., Smith L., La Thangue N.B. Chk2 activates E2F-1 in response to DNA damage. Nat Cell Biol. 5:2003;401-409
64. Lin W.C., Lin F.T., Nevins J.R. Selective induction of E2F-1 in response to DNA damage, mediated by ATM-dependent phosphorylation. Genes Dev. 15:2001;1833-1844
65. DeGregori J., Leone G., Miron A., Jakoi L., Nevins J.R. Distinct roles for E2F proteins in cell growth control and apoptosis. Proc Natl Acad Sci USA. 94:1997;7245-7250
66. Lee J.S., Collins K.M., Brown A.L., Lee C.H., Chung J.H. hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature. 404:2000;201-204
67. Yang S., Kuo C., Bisi J.E., Kim M.K. PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2. Nat Cell Biol. 4:2002;865-870
68. Zhang J., Willers H., Feng Z., Ghosh J.C., Kim S., Weaver D.T., Chung J.H., Powell S.N., Xia F. Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol Cell Biol. 24:2004;708-718
69. Lukas C., Falck J., Bartkova J., Bartek J., Lukas J. Distinct spatiotemporal dynamics of mammalian checkpoint regulators induced by DNA damage. Nat Cell Biol. 5:2003;255-260
70. Xu Z.X., Timanova-Atanasova A., Zhao R.X., Chang K.S. PML colocalizes with and stabilizes the DNA damage response protein TopBP1. Mol Cell Biol. 23:2003;4247-4256
71. Wang Y., Cortez D., Yazdi P., Neff N., Elledge S.J., Qin J. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev. 14:2000;927-939
72. Wang B., Matsuoka S., Carpenter P.B., Elledge S.J. 53BP1, a mediator of the DNA damage checkpoint. Science. 298:2002;1435-1438
73. Ward I.M., Wu X., Chen J. Threonine 68 of Chk2 is phosphorylated at sites of DNA strand breaks. J Biol Chem. 276:2001;47755-47758
74. Foray N., Marot D., Gabriel A., Randrianarison V., Carr A.M., Perricaudet M., Ashworth A., Jeggo P. A subset of ATM- and ATR-dependent phosphorylation events requires the BRCA1 protein. Embo J. 22:2003;2860-2871
75. Brown K.D., Rathi A., Kamath R., Beardsley D.I., Zhan Q., Mannino J.L., Baskaran R. The mismatch repair system is required for S-phase checkpoint activation. Nat Genet. 33:2003;80-84
76. Franchitto A., Pichierri P., Piergentili R., Crescenzi M., Bignami M., Palitti F. The mammalian mismatch repair protein MSH2 is required for correct MRE11 and RAD51 relocalization and for efficient cell cycle arrest induced by ionizing radiation in G2 phase. Oncogene. 22:2003;2110-2120
77. Buscemi G., Savio C., Zannini L., Micciche F., Masnada D., Nakanishi M., Tauchi H., Komatsu K., Mizutani S., Khanna K., Chen P., Concannon P., Chessa L., Delia D. Chk2 activation dependence on Nbs1 after DNA damage. Mol Cell Biol. 21:2001;5214-5222
78. Usui T., Ogawa H., Petrini J.H. A DNA damage response pathway controlled by Tel1 and the Mre11 complex. Mol Cell. 7:2001;1255-1266
79. Uziel T., Lerenthal Y., Moyal L., Andegeko Y., Mittelman L., Shiloh Y. Requirement of the MRN complex for ATM activation by DNA damage. Embo J. 22:2003;5612-5621
80. Carson C.T., Schwartz R.A., Stracker T.H., Lilley C.E., Lee D.V., Weitzman M.D. The Mre11 complex is required for ATM activation and the G(2)/M checkpoint. Embo J. 22:2003;6610-6620
81. Lee J.H., Xu B., Lee C.H., Ahn J.Y., Song M.S., Lee H., Canman C.E., Lee J.S., Kastan M.B., Lim D.S. Distinct functions of Nijmegen breakage syndrome in ataxia telangiectasia mutated-dependent responses to DNA damage. Mol Cancer Res. 1:2003;674-681
82. Mochan T.A., Venere M., DiTullio R.A. Jr., Halazonetis T.D. 53BP1 and NFBD1/MDC1-Nbs1 function in parallel interacting pathways activating ataxia-telangiectasia mutated (ATM) in response to DNA damage. Cancer Res. 63:2003;8586-8591
83. Ward I.M., Minn K., van Deursen J., Chen J. p53 Binding protein 53BP1 is required for DNA damage responses and tumor suppression in mice. Mol Cell Biol. 23:2003;2556-2563
84. Fernandez-Capetillo O., Chen H.T., Celeste A., Ward I., Romanienko P.J., Morales J.C., Naka K., Xia Z., Camerini-Otero R.D., Motoyama N., Carpenter P.B., Bonner W.M., Chen J., Nussenzweig A. DNA damage-induced G2-M checkpoint activation by histone H2AX and 53BP1. Nat Cell Biol. 4:2002;993-997
85. DiTullio R.A. Jr., Mochan T.A., Venere M., Bartkova J., Sehested M., Bartek J., Halazonetis T.D. 53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer. Nat Cell Biol. 4:2002;998-1002
86. Stewart G.S., Wang B., Bignell C.R., Taylor A.M., Elledge S.J. MDC1 is a mediator of the mammalian DNA damage checkpoint. Nature. 421:2003;961-966
87. Goldberg M., Stucki M., Falck J., D'Amours D., Rahman D., Pappin D., Bartek J., Jackson S.P. MDC1 is required for the intra-S-phase DNA damage checkpoint. Nature. 421:2003;952-956
88. Peng A., Chen P.L. NFBD1, like 53BP1, is an early and redundant transducer mediating Chk2 phosphorylation in response to DNA damage. J Biol Chem. 278:2003;8873-8876
89. Shang Y.L., Bodero A.J., Chen P.L. NFBD1, a novel nuclear protein with signature motifs of FHA and BRCT, and an internal 41-amino acid repeat sequence, is an early participant in DNA damage response. J Biol Chem. 278:2003;6323-6329
90. Shieh S.Y., Taya Y., Prives C. DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization. Embo J. 18:1999;1815-1823
91. Unger T., Juven-Gershon T., Moallem E., Berger M., Vogt Sionov R., Lozano G., Oren M., Haupt Y. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. Embo J. 18:1999;1805-1814
92. Shieh S.Y., Ahn J., Tamai K., Taya Y., Prives C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev. 14:2000;289-300
93. Chehab N.H., Malikzay A., Appel M., Halazonetis T.D. Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev. 14:2000;278-288
94. Yu Q., Rose J.H., Zhang H., Pommier Y. Antisense inhibition of Chk2/hCds1 expression attenuates DNA damage-induced S and G2 checkpoints and enhances apoptotic activity in HEK-293 cells. FEBS Lett. 505:2001;7-12
95. Tan S., Guschin D., Davalos A., Lee Y.L., Snowden A.W., Jouvenot Y., Zhang H.S., Howes K., McNamara A.R., Lai A., Ullman C., Reynolds L., Moore M., Isalan M., Berg L.P., Campos B., Qi H., Spratt S.K., Case C.C., Pabo C.O., Campisi J., Gregory P.D. Zinc-finger protein-targeted gene regulation: genomewide single-gene specificity. Proc Natl Acad Sci USA. 100:2003;11997-12002
96. Craig A., Scott M., Burch L., Smith G., Ball K., Hupp T. Allosteric effects mediate CHK2 phosphorylation of the p53 transactivation domain. EMBO Rep. 4:2003;787-792
97. Qin D., Lee H., Yuan C., Ju Y., Tsai M.D. Identification of potential binding sites for the FHA domain of human Chk2 by in vitro binding studies. Biochem Biophys Res Commun. 311:2003;803-808
98. Ahn J., Urist M., Prives C. Questioning the role of Chk2 in the p53 DNA Damage Response. J Biol Chem. 278:2003;20480-20489
99. Jallepalli P.V., Lengauer C., Vogelstein B., Bunz F. The Chk2 tumor suppressor is not required for p53 responses in human cancer cells. J Biol Chem. 278:2003;20475-20479
100. Hirao A., Kong Y.Y., Matsuoka S., Wakeham A., Ruland J., Yoshida H., Liu D., Elledge S.J., Mak T.W. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science. 287:2000;1824-1827
101. Hirao A., Cheung A., Duncan G., Girard P.M., Elia A.J., Wakeham A., Okada H., Sarkissian T., Wong J.A., Sakai T., De Stanchina E., Bristow R.G., Suda T., Lowe S.W., Jeggo P.A., Elledge S.J., Mak T.W. Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol Cell Biol. 22:2002;6521-6532
102. Jack M.T., Woo R.A., Hirao A., Cheung A., Mak T.W., Lee P.W. Chk2 is dispensable for p53-mediated G1 arrest but is required for a latent p53-mediated apoptotic response. Proc Natl Acad Sci USA. 3:2002;3
103. Takai H., Naka K., Okada Y., Watanabe M., Harada N., Saito S., Anderson C.W., Appella E., Nakanishi M., Suzuki H., Nagashima K., Sawa H., Ikeda K., Motoyama N. Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. Embo J. 21:2002;5195-5205
104. Keramaris E., Hirao A., Slack R.S., Mak T.W., Park D.S. Ataxia telangiectasia-mutated protein can regulate p53 and neuronal death independent of Chk2 in response to DNA damage. J Biol Chem. 278:2003;37782-37789
105. Oishi I., Sugiyama S., Otani H., Yamamura H., Nishida Y., Minami Y. A novel Drosophila nuclear protein serine/threonine kinase expressed in the germline during its establishment. Mech Dev. 71:1998;49-63
106. Xu J., Xin S., Du W. Drosophila Chk2 is required for DNA damage-mediated cell cycle arrest and apoptosis. FEBS Lett. 508:2001;394-398
107. Xu J., Du W. Drosophila chk2 plays an important role in a mitotic checkpoint in syncytial embryos. FEBS Lett. 545:2003;209-212
108. Takada S., Kelkar A., Theurkauf W.E. Drosophila checkpoint kinase 2 couples centrosome function and spindle assembly to genomic integrity. Cell. 113:2003;87-99
109. Peters M., DeLuca C., Hirao A., Stambolic V., Potter J., Zhou L., Liepa J., Snow B., Arya S., Wong J., Bouchard D., Binari R., Manoukian A.S., Mak T.W. Chk2 regulates irradiation-induced, p53-mediated apoptosis in Drosophila. Proc Natl Acad Sci USA. 99:2002;11305-11310
110. Brodsky M.H., Weinert B.T., Tsang G., Rong Y.S., McGinnis N.M., Golic K.G., Rio D.C., Rubin G.M. Drosophila melanogaster MNK/Chk2 and p53 regulate multiple DNA repair and apoptotic pathways following DNA damage. Mol Cell Biol. 24:2004;1219-1231
111. Oishi I., Iwai K., Kagohashi Y., Fujimoto H., Kariya K., Kataoka T., Sawa H., Okano H., Otani H., Yamamura H., Minami Y. Critical role of Caenorhabditis elegans homologs of Cds1 (Chk2)-related kinases in meiotic recombination. Mol Cell Biol. 21:2001;1329-1335
112. Higashitani A., Aoki H., Mori A., Sasagawa Y., Takanami T., Takahashi H. Caenorhabditis elegans Chk2-like gene is essential for meiosis but dispensable for DNA repair. FEBS Lett. 485:2000;35-39
113. MacQueen A.J., Villeneuve A.M. Nuclear reorganization and homologous chromosome pairing during meiotic prophase require C. elegans chk-2. Genes Dev. 15:2001;1674-1687
114. Abdu U., Brodsky M., Schupbach T. Activation of a meiotic checkpoint during Drosophila oogenesis regulates the translation of Gurken through Chk2/Mnk. Curr Biol. 12:2002;1645-1651